SEC Tracker
Get the app

Caribou Biosciences CRBU

Caribou Biosciences reported a $26.61 million net loss for Q3 2026.

Form
10-Q
Filed
Importance
Notable
  1. Revenue of $1.61 million for the three months ended Sep 30, 2026.
  2. Net loss of $26.61 million for the three months ended Sep 30, 2026.
  3. Cash and equivalents of $26.06 million as of Sep 30, 2026.
  4. Diluted EPS of -$0.25 for the three months ended Sep 30, 2026.

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Caribou Biosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Protara Therapeutics PRTO public float $112M, Jun 30, 2025
  2. Fate Therapeutics FATE public float $113M, Jun 30, 2025
  3. Protalix BioTherapeutics PLX public float $113M, Jun 30, 2025
  4. TuHURA Biosciences HURA public float $111M, Jun 30, 2025
  5. Enanta Pharmaceuticals ENTA public float $111M, Mar 31, 2025, over 18 months old

Data on this page was fetched . The filing on SEC.gov is the record.